Effect of Remazolam on hemodynamics and postoperative rehabilitation of patients undergoing craniocerebral intervention

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040134

Enrollment

Unknown

Registered

2020-11-22

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniocerebral intervention

Interventions

Experimental group A:Remazolam 0.2mg/kg

Experimental group B:Remazolam 0.3mg/kg

The control group C:propofol 2mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. The American Society of Anesthesiologists (American Society of Anesthesiologists, ASA) class I or II; 3. Mri/CT and COMPUTED tomography (CT) angiography revealed unruptured aneurysms, arteriovenous malformations, or carotid artery stenosis; 4. Endotracheal intubation was used during the operation under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Cerebral aneurysm rupture or arteriovenous malformation hemorrhage; 2. Chronic kidney failure; 3. Mental illness or treatment with psychotropic drugs; 4. Alcohol, opioids or sedatives - hypnotic drug addiction; 5. Obesity (body mass index (BMI) >30 kg.m - 2); 6. Allergies to drugs used in the study; 7. Operation time 3 h.

Design outcomes

Primary

Measure	Time frame
Hemodynamic data;	—

Countries

China

Contacts

Public ContactLiu Guo-ying

Department of Anesthesiology, Liaocheng People's Hospital

lgy1975@126.com+86 15315701063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026